We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Atea Pharmaceuticals, Inc. (AVIR - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Atea Pharmaceuticals, Inc. is one of 1025 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Atea Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for AVIR's full-year earnings has moved 20.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, AVIR has moved about 16.4% on a year-to-date basis. In comparison, Medical companies have returned an average of 7.5%. This means that Atea Pharmaceuticals, Inc. is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Doximity (DOCS - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 56.4%.
Over the past three months, Doximity's consensus EPS estimate for the current year has increased 7.1%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Atea Pharmaceuticals, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 504 individual companies and currently sits at #91 in the Zacks Industry Rank. On average, this group has lost an average of 0.1% so far this year, meaning that AVIR is performing better in terms of year-to-date returns.
On the other hand, Doximity belongs to the Medical Services industry. This 60-stock industry is currently ranked #175. The industry has moved +1.9% year to date.
Atea Pharmaceuticals, Inc. and Doximity could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Atea Pharmaceuticals, Inc. (AVIR - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Atea Pharmaceuticals, Inc. is one of 1025 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Atea Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for AVIR's full-year earnings has moved 20.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, AVIR has moved about 16.4% on a year-to-date basis. In comparison, Medical companies have returned an average of 7.5%. This means that Atea Pharmaceuticals, Inc. is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Doximity (DOCS - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 56.4%.
Over the past three months, Doximity's consensus EPS estimate for the current year has increased 7.1%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Atea Pharmaceuticals, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 504 individual companies and currently sits at #91 in the Zacks Industry Rank. On average, this group has lost an average of 0.1% so far this year, meaning that AVIR is performing better in terms of year-to-date returns.
On the other hand, Doximity belongs to the Medical Services industry. This 60-stock industry is currently ranked #175. The industry has moved +1.9% year to date.
Atea Pharmaceuticals, Inc. and Doximity could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.